Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP8 | P22894 | 7/20 | 0.48 |
| ▸ | MMP12 | P39900 | 7/20 | 0.48 |
| ▸ | MMP13 | P45452 | 7/20 | 0.48 |
| ▸ | MMP14 | P50281 | 7/20 | 0.48 |
| ▸ | MMP16 | P51512 | 7/20 | 0.48 |
| ▸ | MMP9 | P14780 | 6/20 | 0.48 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 6/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533111 | 0.83 | MAPK1 (0.48) | POLB | |
| SCHEMBL7540459 | 0.82 | TUBB1 (0.42) | PKMGAAPOLB | |
| SCHEMBL7536306 | 0.81 | PKM (0.56) | PKMMMP2MMP8MMP12MMP13 | |
| SCHEMBL7533779 | 0.81 | HPGD (0.43) | MMP2MMP8MMP13MMP9MMP3 | |
| SCHEMBL6673928 | 0.80 | MCL1 (0.62) | GAAPOLB | |
| SCHEMBL7459434 | 0.77 | TSHR (0.56) | — | |
| SCHEMBL6266199 | 0.77 | TAS2R14 (0.57) | — | |
| SCHEMBL6265191 | 0.76 | TAS2R14 (0.56) | — | |
| SCHEMBL8962292 | 0.75 | POLB (0.68) | PKMMMP2MMP8MMP12MMP13 | |
| SCHEMBL314725 | 0.73 | MMP2 (0.74) | PKMMMP2MMP8MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | PKM 3140/4885MMP2 3203/4885MMP8 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.